TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7844300

Group type: EXPERIMENTAL
Intervention: Auditory and visual messages classified as 'control enhancement'
Number of subjects: 42
Study: 3294284

Group type: EXPERIMENTAL
Intervention: Intravenous dextro‐amphetamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pimozide
Number of subjects: 30
Study: 31800047

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 378244

Group type: EXPERIMENTAL
Intervention: Low BMI (bottom three deciles, <23.5 kg/m2)
Number of subjects: 378244

Group type: EXPERIMENTAL
Intervention: High BMI (top two deciles, >30.7 kg/m2)
Number of subjects: 378244

Group type: EXPERIMENTAL
Intervention: Non-genetic and MR within-sibling analyses
Number of subjects: 378244

Group type: EXPERIMENTAL
Intervention: Non-linear MR
Number of subjects: 378244

Group type: EXPERIMENTAL
Intervention: MR Egger
Number of subjects: 378244

Group type: EXPERIMENTAL
Intervention: Non-genetic within-sibling analysis
Number of subjects: 378244

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 378244
Study: 29569470

Group type: EXPERIMENTAL
Intervention: Enhanced program (HOME), involving pre/post discharge visits and two follow-up phone calls
Number of subjects: 400

Group type: COMPARATOR
Intervention: In-hospital consultation using the home and community environment assessment and the Lawton Instrumental Activities of Daily Living assessment
Number of subjects: 400
Study: 28050914

Group type: EXPERIMENTAL
Intervention: Self-selected recovery
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standardized recovery
Number of subjects: 11
Study: 26030762

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Panic-focused psychodynamic psychotherapy
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Applied relaxation training
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Nonassertive cluster
Number of subjects: 194

Group type: COMPARATOR
Intervention: Normative cohort
Number of subjects: 194

Group type: COMPARATOR
Intervention: Cohort of patients with major depression
Number of subjects: 194
Study: 23924878

Group type: EXPERIMENTAL
Intervention: Cervical pessary inserted between 16 and 20 weeks' gestation
Number of subjects: 808

Group type: COMPARATOR
Intervention: Control group (no pessary)
Number of subjects: 808
Study: 20356395

Group type: EXPERIMENTAL
Intervention: Yoga classes (12 weekly sessions)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conventional therapeutic exercise classes (12 weekly sessions)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Self-care book
Number of subjects: 210
Study: 18344733

Group type: EXPERIMENTAL
Intervention: Olanzapine (mean dose 11.3 mg)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Risperidone (mean dose 3.0 mg)
Number of subjects: 122
Study: 16546280

Group type: EXPERIMENTAL
Intervention: IH636 grape seed proanthocyanidin extract (GSPE) 100 mg three times a day orally for 6 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo capsules for 6 months
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: IH636 grape seed proanthocyanidin extract (GSPE)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 14530912

Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg every 28 days for 2 years)
Number of subjects: 1640

Group type: COMPARATOR
Intervention: CMF (six 28-day cycles)
Number of subjects: 1640
Study: 10714421

Group type: EXPERIMENTAL
Intervention: Exercise group (rehabilitation program consisting of exercise and education twice a week for 8 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo group (conventional community care)
Number of subjects: 38
Study: 9325508

Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Supportive therapy (Control)
Number of subjects: 50
Study: 8330466

Group type: EXPERIMENTAL
Intervention: CGS-12970 (100, 200, 300, or 400 mg twice a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3521860

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mefenamic acid
Number of subjects: 40
Study: 29764419

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 197

Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 197
Study: 27418249

Group type: EXPERIMENTAL
Intervention: Intermittent occlusion therapy (IO therapy) using liquid crystal glasses (Amblyz), 4 hours per day, set at 30‐second opaque/transparent intervals (occluded 50% of wear time)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Continuous occlusion therapy using traditional adhesive patches, 2 hours per day (occluded 100% of wear time)
Number of subjects: 34
Study: 24566987

Group type: EXPERIMENTAL
Intervention: Stimulation over the unaffected limb with mirror visual feedback (experimental condition)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Stimulation over the affected limb with mirror visual feedback
Number of subjects: 14

Group type: COMPARATOR
Intervention: Stimulation over the unaffected limb without mirror visual feedback
Number of subjects: 14

Group type: COMPARATOR
Intervention: Stimulation over the affected limb without mirror visual feedback
Number of subjects: 14
Study: 22130394

Group type: EXPERIMENTAL
Intervention: 30 minutes of stretching activities
Number of subjects: 52

Group type: COMPARATOR
Intervention: 30 minutes of quiet sitting (nonstretched)
Number of subjects: 52
Study: 20021624

Group type: EXPERIMENTAL
Intervention: High-glycemic index meal
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-glycemic index meal
Number of subjects: 15
Study: 18972248

Group type: EXPERIMENTAL
Intervention: Prolonged static stretching (SS) for 10 min, with each leg stretched unilaterally for 40 s with eight different exercises, repeated three times
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prolonged static stretching (SS)
Number of subjects: 10
Study: 15930204

Group type: EXPERIMENTAL
Intervention: Immediate antibiotics (ABX; amoxicillin plus symptom medication)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Watchful waiting (WW; symptom medication only)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Immediate antibiotics (ABX)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Watchful waiting (WW)
Number of subjects: 223
Study: 15385223

Group type: EXPERIMENTAL
Intervention: Disulfiram (200 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 10227568

Group type: EXPERIMENTAL
Intervention: Acarbose (50 mg t.d.s. for the first 2 weeks, then 100 mg t.d.s. for the subsequent weeks)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 121
Study: 9056156

Group type: EXPERIMENTAL
Intervention: Iomeprol (new nonionic contrast medium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low osmolar nonionic contrast media
Number of subjects: 0
Study: 1859010

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 15 micrograms/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral solution of fentanyl citrate (control) 15 micrograms/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral solution of fentanyl citrate (control)
Number of subjects: 12
Study: 7341285

Group type: EXPERIMENTAL
Intervention: Mianserin 20 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Mianserin 20 mg tid for 3 days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Mianserin pre-treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Clonidine 300 micrograms
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Mianserin alone
Number of subjects: 6
Study: 31851067

Group type: EXPERIMENTAL
Intervention: Wireless Automated Hearing‐Test System
Number of subjects: 120

Group type: COMPARATOR
Intervention: Automated Testing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Manual Testing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Two-step Protocol (automated followed by manual testing)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional Audiometry
Number of subjects: 120
Study: 30137473

Group type: EXPERIMENTAL
Intervention: Dual-Process Bereavement Group Intervention - Chinese (DPBGI-C)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Loss-Oriented Bereavement Group Intervention - Chinese (LOBGI-C)
Number of subjects: 125
Study: 28865493

Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg from weeks 0 to 6, then 3, 6, or 10 mg/kg every 8 weeks from weeks 14 to 46
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 0
Study: 26650562

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 60
Study: 25111437

Group type: EXPERIMENTAL
Intervention: Cryolipolysis treatment on larger thigh
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (contralateral thigh)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Patient surveys
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Clinical photographs
Number of subjects: 11
Study: 21212911

Group type: EXPERIMENTAL
Intervention: Third generation OCP (150 microgram desogestrel + 30 microgram ethinylestradiol)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Second generation OCP (150 microgram levonorgestrel + 30 microgram ethinylestradiol)
Number of subjects: 100
Study: 18082782

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ice cube
Number of subjects: 50
Study: 17173586

Group type: EXPERIMENTAL
Intervention: Teaching module utilized during consultation in group A (50 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patients in group A who underwent treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group B (50 patients)
Number of subjects: 100
Study: 12942727

Group type: EXPERIMENTAL
Intervention: Serebryany klyuch mineral water (group 2)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Tap water (group 1)
Number of subjects: 27
Study: 10715982

Group type: EXPERIMENTAL
Intervention: Perfix plug-and-patch
Number of subjects: 141
Study: 8813098

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 0
Study: 1571851

Group type: EXPERIMENTAL
Intervention: sCT (200 IU every other day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 2995279

Group type: EXPERIMENTAL
Intervention: 10 g dietary fibre supplements in the form of a corn‐based biscuit (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 g dietary fibre supplements as wheat bran (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intervention (Group C)
Number of subjects: 40
Study: 31752260

Group type: EXPERIMENTAL
Intervention: Prolonged exercise (45 min of one-arm cranking and 8 h walking/day) during caloric restriction (3.2 kcal/kg body weight day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet and restricted exercise
Number of subjects: 0
Study: 28699542

Group type: EXPERIMENTAL
Intervention: Pesticide-free community mobilisation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional dengue controls
Number of subjects: 0
Study: 25151254

Group type: EXPERIMENTAL
Intervention: Prophylactic endoscopic coagulation (PEC)
Number of subjects: 347

Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 347
Study: 23511486

Group type: EXPERIMENTAL
Intervention: News story about a mass shooting
Number of subjects: 1797

Group type: EXPERIMENTAL
Intervention: News story about a mass shooting with gun restriction proposal
Number of subjects: 1797

Group type: EXPERIMENTAL
Intervention: News story about a mass shooting with large-capacity magazine ban proposal
Number of subjects: 1797

Group type: COMPARATOR
Intervention: No exposure (control group)
Number of subjects: 1797
Study: 21357805

Group type: EXPERIMENTAL
Intervention: Structured lifestyle counseling by nurse practitioners (NPs) using a standardized software program
Number of subjects: 457

Group type: COMPARATOR
Intervention: Usual care by general practitioners (GP‐UC)
Number of subjects: 457
Study: 19673651

Group type: EXPERIMENTAL
Intervention: Cell culture-derived influenza vaccine (CCIV)
Number of subjects: 2654

Group type: COMPARATOR
Intervention: Conventional egg-based vaccine
Number of subjects: 2654
Study: 16378672

Group type: EXPERIMENTAL
Intervention: Biphasic defibrillation (n=33)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Monophasic defibrillation (n=25)
Number of subjects: 74
Study: 12752139

Group type: EXPERIMENTAL
Intervention: Alefacept therapy
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 11128739

Group type: EXPERIMENTAL
Intervention: New pattern of electrical stimulation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 27
Study: 9350389

Group type: EXPERIMENTAL
Intervention: Slow-release lithium carbonate, 800 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 1332985

Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate and oestradiol valerate (PC/EV) administered until the twelfth week of gestation
Number of subjects: 120

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 120
Study: 3715407

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 50 to 3900 mg daily for 1 week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg daily for 1 week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) higher doses (above 100 mg)
Number of subjects: 0
Study: 29460337

Group type: EXPERIMENTAL
Intervention: Talking Sense intervention (3 one-to-one individualized sessions)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control discussion (knowledge-only)
Number of subjects: 52
Study: 28531423

Group type: EXPERIMENTAL
Intervention: ≥25% sodium reduction (n=21 patients)
Number of subjects: 38

Group type: COMPARATOR
Intervention: <25% sodium reduction (n=14 patients)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: ≥25% sodium reduction
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study: 24908265

Group type: EXPERIMENTAL
Intervention: T4 transection plus 'Energy‐boosting and Yin‐nourishing anti‐perspirant formula' (Group A)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: T4 transection (Group B)
Number of subjects: 300

Group type: COMPARATOR
Intervention: T2 transection (Group C, control group)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 300
Study: 22300013

Group type: EXPERIMENTAL
Intervention: Dual-task training (cognitive activities with gait and balance exercises)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Single-task training (gait and balance activities without cognitive tasks)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dual-task training
Number of subjects: 17

Group type: COMPARATOR
Intervention: Single-task training
Number of subjects: 17
Study: 20375125

Group type: EXPERIMENTAL
Intervention: Fatigue: Take Control (FTC) program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list (WL) group
Number of subjects: 30
Study: 19043355

Group type: EXPERIMENTAL
Intervention: Instructional programme combining safe postural shifts and the backward‐chaining method (Group I)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional training to rise unassisted after a fall (Group II - control)
Number of subjects: 120
Study: 16540864

Group type: EXPERIMENTAL
Intervention: Matched treatment (manipulation, stabilization exercise, or specific exercise)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Unmatched treatment (manipulation, stabilization exercise, or specific exercise)
Number of subjects: 123
Study: 12669236

Group type: EXPERIMENTAL
Intervention: Carboplatin and prolonged oral etoposide (group 1; n=58)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Etoposide alone (group 2; n=59)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Carboplatin and prolonged oral etoposide (group 1; n=84)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Carboplatin and high-dose intravenous etoposide (group 2; n=84)
Number of subjects: 285
Study: 10723836

Group type: EXPERIMENTAL
Intervention: Use of recommended coping strategies (setting goals for drinking, keeping track of drinking, pacing drinking, planning ahead to avoid heavy drinking, developing free-time activities, coping with problems without drinking)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Use of recommended coping strategies (setting goals for drinking, keeping track of drinking, coping with problems without drinking)
Number of subjects: 155
Study: 8626987

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Furosemide (30 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Acetazolamide (250 mg)
Number of subjects: 15
Study: 1428784

Group type: EXPERIMENTAL
Intervention: pyrimethamine‐sulfadiazine
Number of subjects: 39

Group type: COMPARATOR
Intervention: pyrimethamine‐clindamycin
Number of subjects: 39
Study: 6703005

Group type: EXPERIMENTAL
Intervention: +1.25 D with 2 delta base-in each eye (plus with prism group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: +1.50 D near addition (bifocal group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group (no. 1 pink tint)
Number of subjects: 0
Study: 30605397

Group type: COMPARATOR
Intervention: VIG (70% V̇o2peak‐reserve)
Number of subjects: 130

Group type: COMPARATOR
Intervention: BIKE
Number of subjects: 130

Group type: COMPARATOR
Intervention: MOD (50% V̇o2peak‐reserve)
Number of subjects: 130
Study: 29116949

Group type: EXPERIMENTAL
Intervention: Couple-focused interventions targeting diet and physical activity (PA) behaviors post-cardiac rehabilitation.
Number of subjects: 11
Study: 27093063

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 46
Study: 24424109

Group type: EXPERIMENTAL
Intervention: Generic preparation of 4.2 mg fentanyl
Number of subjects: 20

Group type: COMPARATOR
Intervention: Durogesic patch of 4.2 mg fentanyl
Number of subjects: 20
Study: 22964716

Group type: EXPERIMENTAL
Intervention: Combination of UDCA (1 g/day during 3 weeks before surgery) and RIFA (600 mg/day during 1 week before surgery)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 20
Study: 20026112

Group type: EXPERIMENTAL
Intervention: G-CSF treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: G-CSF deficiency
Number of subjects: 0
Study: 18773747

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New effective and efficient preventive strategies
Number of subjects: 0
Study: 16078340

Group type: EXPERIMENTAL
Intervention: Coping skills training (CST)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Self-monitoring
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Coping skills training (CST) after self-monitoring
Number of subjects: 30
Study: 12425756

Group type: EXPERIMENTAL
Intervention: ddAT (doxorubicin 50 mg/m2 and docetaxel 75 mg/m2) with prophylactic granulocyte colony-stimulating factor support (5 micro g/kg days 5-10)
Number of subjects: 913

Group type: COMPARATOR
Intervention: AC-DOC (doxorubicin/cyclophosphamide followed by docetaxel)
Number of subjects: 913

Group type: EXPERIMENTAL
Intervention: ddAT
Number of subjects: 913

Group type: COMPARATOR
Intervention: AC-DOC
Number of subjects: 913

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 913
Study: 10075362

Group type: EXPERIMENTAL
Intervention: Incompetent calf perforators ligated
Number of subjects: 35

Group type: COMPARATOR
Intervention: Incompetent calf perforators left intact
Number of subjects: 35
Study: 7545361

Group type: EXPERIMENTAL
Intervention: Gabexate Mesilate (FOY) 3g/day infused for 7 days
Number of subjects: 182

Group type: COMPARATOR
Intervention: Aprotinin (A) 1,500,000 U.I.K./day infused for 7 days
Number of subjects: 182
Study: 1645640

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no cryotherapy)
Number of subjects: 0
Study: 7013962

Group type: EXPERIMENTAL
Intervention: Radiotherapy before mastectomy
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Radiotherapy after mastectomy
Number of subjects: 930

Group type: COMPARATOR
Intervention: No radiotherapy (Control)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Gripping force (all groups)
Number of subjects: 930
Study: 30608308

Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CI therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CI therapy
Number of subjects: 0
Study: 28962558

Group type: EXPERIMENTAL
Intervention: BETTER intervention (personalized prevention visit with prevention practitioner)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait list control (six month wait list)
Number of subjects: 0
Study: 23795976

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Milk-LNS
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Soy-LNS
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: CSB
Number of subjects: 840
Study: 24739994

Group type: EXPERIMENTAL
Intervention: Xeomin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Botox
Number of subjects: 48
Study: 23378458

Group type: EXPERIMENTAL
Intervention: Wellmune (250 mg daily for 12 weeks)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (self-administered)
Number of subjects: 77
Study: 19765608

Group type: EXPERIMENTAL
Intervention: Boy Scout Five‐A‐Day Badge program (9-week program with 30 min weekly troop time and 25 min weekly Internet programming)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Boy Scout Five‐A‐Day Badge program
Number of subjects: 473
Study: 17530530

Group type: EXPERIMENTAL
Intervention: Zileuton controlled release (CR) 1,200 mg BID
Number of subjects: 926

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 926
Study: 14998852

Group type: EXPERIMENTAL
Intervention: MMC + GEM (Mitomycin C 8 mg/m2 on day 1 + Gemcitabine 2000 mg/m2 on days 1 and 15 every 4 weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: MMC + CAPE (Mitomycin C 8 mg/m2 on day 1 + Capecitabine 2000 mg/m2/day on days 1-14 every 4 weeks)
Number of subjects: 51